BOSTON, Sept. 28, 2011 /PRNewswire/ -- SPENCER PHARMACEUTICAL INC. (the “Corporation” or “Spencer”) (OTC PINK: SPPH). The Corporation is pleased to announce that it has entered into an agreement with Notre-Dame Capital Inc. (“Notre-Dame”) as its financial advisor.
“We are excited to engage Notre-Dame Capital Inc. and its excellent team lead by Mr. Richard Groome who has over 20 years experience in the financial sector and is a former member of the Board of Directors of the CDNX Exchange, the predecessor of the TSX Venture exchange,” stated Dr. Max Arella, CEO and President of Spencer Pharmaceutical, “to implement a cohesive program that we believe will increase the visibility of Spencer Pharmaceutical Inc. within the investment community, in turn enhancing our likelihood for future growth.”
About Spencer Pharmaceutical
Spencer Pharmaceutical is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
For further information please contact:
Spencer Pharmaceutical Inc.
Dr. Max Arella
T: (617) 973-5017
F: (617) 973-6403
E-mail: arellam@spencerpharmaceutical.com
Website: www.spencerpharmaceutical.com
About Notre-Dame Capital Inc.
Notre-Dame Capital is a Canadian exempt market dealer specializing in the small and middle markets. The firm provides innovative financing solutions to small and mid-size North American issuers that specialize in oil & gas, mining, bio-technology, internet technologies, agriculture, organic, natural products and clean technology. Notre-Dame Capital also serves institutional money managers and strategic investors worldwide who desire to invest into quality and high-growth North American opportunities.
For further information contact:
Notre-Dame Capital Inc.
T: (514) 907-4989
F: (514) 807-3449
Website: www.notredamecapital.com
Important Information
About Forward-Looking Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company’s website does not constitute a part of this release.
SOURCE Spencer Pharmaceutical Inc.
